Form 4 Filing for Adaptive Biotechnologies Corp

Harlan S. Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp, reported the sale of Common Stock through a Rule 10b5-1 trading plan. On June 15, 2026, 100,000 shares were sold at a weighted-average price of $17.37, with prices ranging from $17.14 to $17.96. Following this transaction, 1,412,058 shares were held. On June 16, 2026, an additional 6,160 shares were sold at a weighted-average price of $18.01, with prices ranging from $18.00 to $18.04. After this second transaction, the total shares held by Mr. Robins amounted to 1,405,898. These transactions were direct holdings.